cancer

Endocyte, Inc. (NASDAQ: ECYT) on Thursday announced its $2.1-billion cash sale to Novartis AG (NYSE: NVS). The deal values Endocyte at $24 per share, representing a 54-percent premium from the firm’s $15.56 Wednesday closing price. Why It’s Important Endocyte's radioligand...

Merrimack Pharmaceuticals Inc (NASDAQ: MACK) plunged more than 30 percent Monday after management discontinued the development of MM-141. The drug’s Phase 2 trial for MM-141 in front-line metastatic pancreatic cancer did not meet primary or secondary endpoints. Why It’s Important...

G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares gained 2 percent Monday morning after the company confirmed the Food and Drug Administration approved its bowel-cleansing preparation product. What Happened Valeant said the FDA granted approval for PLENVU, the company's polyethylene...

Ziopharm Oncology Inc. (NASDAQ: ZIOP) has two goals. One is to disrupt the narrative around recurrent glioblastomas. The other is to disrupt the entire pharmaceutical supply chain. The latter pursuit isn’t just a B2B revenue opportunity, it's meant to alleviate cost barriers to critical...

NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY) announced disappointing results from a study of the similar therapy epacadostat.  The Analyst Baird Equity Research's Michael Ulz...

NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...

Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial. What Happened Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...

ARMO Biosciences Inc (NASDAQ: ARMO)'s lead product candidate AM0010 is a drug for the treatment of pancreatic ductal adenocarcinoma recently showed "promising" data that's supportive of a potentially large commercial opportunity, according to Leerink. The Analyst Leerink's...